Aclidinium bromide/formoterol

Drug Profile

Aclidinium bromide/formoterol

Alternative Names: Aclidinium bromide/formoterol fumarate; BrimicaGenuair; DuaklirGenuair; Formoterol fumarate/aclidinium bromide; KRP-AB1102F; LAS40464

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Laboratorios Almirall
  • Developer Allergan; Almirall S.A.; AstraZeneca; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 08 May 2017 Astrazeneca terminates a phase II trial in Chronic obstructive pulmonary disease as actual sample size of 156 was sufficient to estimate the clinical outcomes in USA (Inhalation) (NCT00706914)
  • 17 Mar 2017 AstraZeneca and Circassia Pharmaceuticals agree to co-promote and co-develop aclidinium bromide/formoterol in USA for chronic obstructive pulmonary disease
  • 13 Jan 2017 AstraZeneca and Parexel plan the phase III AVANT trial for Chronic obstructive pulmonary disease in India, Philippines, Taiwan and Vietnam (NCT03022097)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top